{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:46:19Z","timestamp":1772034379913,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00259-015-3055-0","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T14:37:10Z","timestamp":1429627030000},"page":"1172-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["131I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study"],"prefix":"10.1007","volume":"42","author":[{"given":"Kuan-Yin","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoh-Fang","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"3055_CR1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1002\/cncr.24416","volume":"115","author":"AY Chen","year":"2009","unstructured":"Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988\u20132005. Cancer. 2009;115:3801\u20137.","journal-title":"Cancer"},{"key":"3055_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"3055_CR3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","volume":"79","author":"FD Gilliland","year":"1997","unstructured":"Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973\u20131991. Cancer. 1997;79:564\u201373.","journal-title":"Cancer"},{"key":"3055_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.amjoto.2005.01.019","volume":"26","author":"DR Blankenship","year":"2005","unstructured":"Blankenship DR, Chin E, Terris DJ. Contemporary management of thyroid cancer. Am J Otolaryngol. 2005;26:249\u201360.","journal-title":"Am J Otolaryngol"},{"key":"3055_CR5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","volume":"338","author":"MJ Schlumberger","year":"1998","unstructured":"Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297\u2013306.","journal-title":"N Engl J Med"},{"key":"3055_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.1997.7.177","volume":"7","author":"RR Cavalieri","year":"1997","unstructured":"Cavalieri RR. Iodine metabolism and thyroid physiology: current concepts. Thyroid. 1997;7:177\u201381.","journal-title":"Thyroid"},{"key":"3055_CR7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0030-4220(93)90144-S","volume":"75","author":"A Markitziu","year":"1993","unstructured":"Markitziu A, Lustmann J, Uzieli B, Krausz Y, Chisin R. Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg Oral Med Oral Pathol. 1993;75:318\u201322.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"3055_CR8","first-page":"738","volume":"42","author":"R Solans","year":"2001","unstructured":"Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O\u2019Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42:738\u201343.","journal-title":"J Nucl Med"},{"key":"3055_CR9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/thy.2012.0050","volume":"23","author":"PW Rosario","year":"2013","unstructured":"Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013;23:617\u20139.","journal-title":"Thyroid"},{"key":"3055_CR10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1089\/thy.2009.1611","volume":"19","author":"D Nostrand Van","year":"2009","unstructured":"Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19:1381\u201391.","journal-title":"Thyroid"},{"key":"3055_CR11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ncpendmet0761","volume":"4","author":"F Vathaire de","year":"2008","unstructured":"de Vathaire F. The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:180\u20131.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"2","key":"3055_CR12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"key":"3055_CR13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1749-6632.1960.tb49959.x","volume":"85","author":"NB Myant","year":"1960","unstructured":"Myant NB. Iodine metabolism of salivary glands. Ann N Y Acad Sci. 1960;85:208\u201314.","journal-title":"Ann N Y Acad Sci"},{"key":"3055_CR14","first-page":"755","volume":"25","author":"P Allweiss","year":"1984","unstructured":"Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med. 1984;25:755\u20138.","journal-title":"J Nucl Med"},{"key":"3055_CR15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/00016488709107801","volume":"103","author":"H Maier","year":"1987","unstructured":"Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol. 1987;103:318\u201324.","journal-title":"Acta Otolaryngol"},{"key":"3055_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/105072503321582060","volume":"13","author":"SJ Mandel","year":"2003","unstructured":"Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265\u201371.","journal-title":"Thyroid"},{"key":"3055_CR17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00003072-200211000-00003","volume":"27","author":"M Caglar","year":"2002","unstructured":"Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med. 2002;27:767\u201371.","journal-title":"Clin Nucl Med"},{"key":"3055_CR18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1601-0825.2010.01726.x","volume":"17","author":"D Nostrand Van","year":"2011","unstructured":"Van Nostrand D. Sialoadenitis secondary to I-131 therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17:154\u201361.","journal-title":"Oral Dis"},{"key":"3055_CR19","first-page":"1452","volume":"39","author":"SM Bakheet","year":"1998","unstructured":"Bakheet SM, Hammami MM, Hemidan A, Powe JE, Bajaafar F. Radioiodine secretion in tears. J Nucl Med. 1998;39:1452\u20134.","journal-title":"J Nucl Med"},{"key":"3055_CR20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-002-0969-0","volume":"29","author":"G Zettinig","year":"2002","unstructured":"Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging. 2002;29:1428\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3055_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1590\/S0004-27492012000200005","volume":"75","author":"FL Fonseca","year":"2012","unstructured":"Fonseca FL, Lunardelli P, Matayoshi S. Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma. Arq Bras Oftalmol. 2012;75:97\u2013100.","journal-title":"Arq Bras Oftalmol"},{"key":"3055_CR22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12149-013-0705-9","volume":"27","author":"G Koca","year":"2013","unstructured":"Koca G, Acar U, Atilgan HI, Erginturk Acar D, Altiparmak UE, Demirel K, et al. Changes in conjunctival cytology and tear function tests with radioiodine treatment for hyperthyroidism. Ann Nucl Med. 2013;27:694\u20139.","journal-title":"Ann Nucl Med"},{"key":"3055_CR23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","volume":"89","author":"C Rubino","year":"2003","unstructured":"Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638\u201344.","journal-title":"Br J Cancer"},{"key":"3055_CR24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/jc.2007-1154","volume":"93","author":"AP Brown","year":"2008","unstructured":"Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504\u201315.","journal-title":"J Clin Endocrinol Metab"},{"key":"3055_CR25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2008.0392","volume":"19","author":"AM Sawka","year":"2009","unstructured":"Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19:451\u20137.","journal-title":"Thyroid"},{"key":"3055_CR26","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-06-0414","volume":"15","author":"LB Travis","year":"2006","unstructured":"Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:2020\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3055_CR27","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1210\/jc.2005-2009","volume":"91","author":"TC Sandeep","year":"2006","unstructured":"Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91:1819\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"3055_CR28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.21064","volume":"117","author":"CM Ronckers","year":"2005","unstructured":"Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005;117:281\u20138.","journal-title":"Int J Cancer"},{"key":"3055_CR29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00259-003-1448-y","volume":"31","author":"E Berthe","year":"2004","unstructured":"Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2004;31:685\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3055_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1259\/0007-1285-59-697-45","volume":"59","author":"CJ Edmonds","year":"1986","unstructured":"Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol. 1986;59:45\u201351.","journal-title":"Br J Radiol"},{"key":"3055_CR31","first-page":"337","volume":"168","author":"C Glanzmann","year":"1992","unstructured":"Glanzmann C. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol. 1992;168:337\u201343.","journal-title":"Strahlenther Onkol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3055-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3055-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:06:25Z","timestamp":1558713985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3055-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}